The Paradox of quetiapine in obsessive-compulsive disorder

Constantin Tranulis; Stéphane Potvin; Martin Gourgue; Gérard Leblanc; Adham Mancini-Marïe; Emmanuel Stip

doi:10.1017/S1092852900022719

The Paradox of quetiapine in obsessive-compulsive disorder

Constantin Tranulis, Stéphane Potvin, Martin Gourgue, Gérard Leblanc, Adham Mancini-Marïe, Emmanuel Stip

Research output: Contribution to journal › Article › peer-review

23 Citations (Scopus)

Abstract

Schizophrenia and obsessive-compulsive disorder (OCD) have historical, clinical, and epidemiological links. The clinical use of atypical neuroleptics (ie, dual serotonin-dopamine antagonists) to treat both conditions sheds a new light on them. We report the first two cases of obsessive-compulsive symptoms (OCS) induced by quetiapine in schizophrenia patients. A case of successful augmentation by quetiapine in refractory OCD is also presented. A review of the literature on OCS induced by atypical neuroleptics follows. This paradoxically induced OCD symptomology in schizophrenia patients administered atypical neuroleptics is discussed from new pathophysiological and clinical perspectives. The discussion emphasizes the prognostic implications of OCS in schizophrenia and available therapies for this comorbidity.

Original language	English
Pages (from-to)	356-361
Number of pages	6
Journal	CNS Spectrums
Volume	10
Issue number	5
DOIs	https://doi.org/10.1017/S1092852900022719
Publication status	Published - May 2005
Externally published	Yes

ASJC Scopus subject areas

Clinical Neurology
Psychiatry and Mental health

Access to Document

10.1017/S1092852900022719

Cite this

@article{69abfe82b0e34254b1c1bc7af230e13c,

title = "The Paradox of quetiapine in obsessive-compulsive disorder",

abstract = "Schizophrenia and obsessive-compulsive disorder (OCD) have historical, clinical, and epidemiological links. The clinical use of atypical neuroleptics (ie, dual serotonin-dopamine antagonists) to treat both conditions sheds a new light on them. We report the first two cases of obsessive-compulsive symptoms (OCS) induced by quetiapine in schizophrenia patients. A case of successful augmentation by quetiapine in refractory OCD is also presented. A review of the literature on OCS induced by atypical neuroleptics follows. This paradoxically induced OCD symptomology in schizophrenia patients administered atypical neuroleptics is discussed from new pathophysiological and clinical perspectives. The discussion emphasizes the prognostic implications of OCS in schizophrenia and available therapies for this comorbidity.",

author = "Constantin Tranulis and St{\'e}phane Potvin and Martin Gourgue and G{\'e}rard Leblanc and Adham Mancini-Mar{\"i}e and Emmanuel Stip",

year = "2005",

month = may,

doi = "10.1017/S1092852900022719",

language = "English",

volume = "10",

pages = "356--361",

journal = "CNS Spectrums",

issn = "1092-8529",

publisher = "MBL Communications",

number = "5",

}

TY - JOUR

T1 - The Paradox of quetiapine in obsessive-compulsive disorder

AU - Tranulis, Constantin

AU - Potvin, Stéphane

AU - Gourgue, Martin

AU - Leblanc, Gérard

AU - Mancini-Marïe, Adham

AU - Stip, Emmanuel

PY - 2005/5

Y1 - 2005/5

N2 - Schizophrenia and obsessive-compulsive disorder (OCD) have historical, clinical, and epidemiological links. The clinical use of atypical neuroleptics (ie, dual serotonin-dopamine antagonists) to treat both conditions sheds a new light on them. We report the first two cases of obsessive-compulsive symptoms (OCS) induced by quetiapine in schizophrenia patients. A case of successful augmentation by quetiapine in refractory OCD is also presented. A review of the literature on OCS induced by atypical neuroleptics follows. This paradoxically induced OCD symptomology in schizophrenia patients administered atypical neuroleptics is discussed from new pathophysiological and clinical perspectives. The discussion emphasizes the prognostic implications of OCS in schizophrenia and available therapies for this comorbidity.

AB - Schizophrenia and obsessive-compulsive disorder (OCD) have historical, clinical, and epidemiological links. The clinical use of atypical neuroleptics (ie, dual serotonin-dopamine antagonists) to treat both conditions sheds a new light on them. We report the first two cases of obsessive-compulsive symptoms (OCS) induced by quetiapine in schizophrenia patients. A case of successful augmentation by quetiapine in refractory OCD is also presented. A review of the literature on OCS induced by atypical neuroleptics follows. This paradoxically induced OCD symptomology in schizophrenia patients administered atypical neuroleptics is discussed from new pathophysiological and clinical perspectives. The discussion emphasizes the prognostic implications of OCS in schizophrenia and available therapies for this comorbidity.

UR - http://www.scopus.com/inward/record.url?scp=22344447146&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22344447146&partnerID=8YFLogxK

U2 - 10.1017/S1092852900022719

DO - 10.1017/S1092852900022719

M3 - Article

C2 - 15858452

AN - SCOPUS:22344447146

SN - 1092-8529

VL - 10

SP - 356

EP - 361

JO - CNS Spectrums

JF - CNS Spectrums

IS - 5

ER -

The Paradox of quetiapine in obsessive-compulsive disorder

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this